SANBO HOSPITAL MANAGEMENT GROUP LIMITED Sanbo Hospital Management Group Limited Stock
Equities
301293
CNE1000061W6
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.52 CNY | -1.25% |
|
-5.09% | -14.26% |
| Sales 2022 | 1.07B 147M | Sales 2023 | 1.31B 181M | Capitalization | 9.89B 1.37B |
|---|---|---|---|---|---|
| Net income 2022 | 63M 8.69M | Net income 2023 | 78M 10.77M | EV / Sales 2022 * | - |
| Net cash position 2022 | 352M 48.54M | Net cash position 2023 | 1.4B 193M | EV / Sales 2023 | 6.47 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
116
x | Employees | 1,954 |
| Yield 2022 * |
-
| Yield 2023 |
0.15% | Free-Float | 48.9% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.25% | ||
| 1 week | -5.09% | ||
| Current month | -12.95% | ||
| 1 month | -11.07% | ||
| 3 months | -22.51% | ||
| 6 months | -17.81% | ||
| Current year | -14.26% |
1 week
52.71
56.16
1 month
52.7166.65
Current year
47.8078.21
1 year
47.80118.22
3 years
47.27118.22
5 years
47.27118.22
10 years
47.27118.22
| Managers | Title | Age | Since |
|---|---|---|---|
Yang Zhang
CEO | Chief Executive Officer | 59 | 03-11-24 |
Ming Hao Qiao
DFI | Director of Finance/CFO | 42 | 14-12-31 |
Ji Rang Sun
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yang Zhang
CEO | Chief Executive Officer | 59 | 03-11-24 |
Guo Ming Luan
FOU | Founder | 65 | 03-11-24 |
Chun Jiang Yu
FOU | Founder | 69 | 03-11-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 52.5 | -1.91% | 2,094,847 |
| 24-05-27 | 53.52 | -1.25% | 2,960,200 |
| 24-05-24 | 54.2 | -0.55% | 3,708,797 |
| 24-05-23 | 54.5 | -1.96% | 2,184,672 |
| 24-05-22 | 55.59 | +0.34% | 2,287,100 |
End-of-day quote Shenzhen S.E., May 26, 2024
More quotes
Sanbo Hospital Management Group Ltd is a China-based company mainly engaged in medical services. The Company is principally engaged in the operation of neurospecialty hospitals. The Company is also engaged in general hospital operations. The Company's diagnostic and treatment programs include neurosurgery, neurointervention, neurology, neuro-oncology chemotherapy, neuro-oncology radiotherapy, neurocritical care and other diagnostic and treatment programs. The other diagnostic and treatment programs include surgery, internal medicine, obstetrics and gynecology, pediatrics, emergency department, imaging department, laboratory department and others. The Company primarily operates its businesses in the domestic market.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.26% | 1.17B | |
| -22.00% | 15.84B | |
| +2.70% | 12.38B | |
| +4.31% | 11.79B | |
| +3.31% | 10.27B | |
| +26.63% | 8.51B | |
| -8.80% | 7.54B | |
| +7.08% | 6.78B | |
| -3.40% | 5.96B | |
| -5.94% | 4.28B |
- Stock Market
- Equities
- 301293 Stock
